UK Innovation & Science Seed Fund

MIRICO Ltd. is a UK-based laser spectroscopy instrumentation company formed in 2015 as a spin-out from the Science and Technology Facilities Council. The technology underpinning MIRICO was developed by the RAL Space Laser Spectroscopy Team, led by Dr. Damien Weidmann. The laser spectroscopy team consists of 8 senior scientists who carry out cutting edge research and development. Over the years they have developed a range of spectroscopy techniques that overcome the major downfalls of current technologies. The company was formed to commercialise and take these technologies to market.

MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction.

Q5D manufactures tools to automate the production of wiring harness for all industrial sectors.

Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.

AgPlus Diagnostics Ltd. develops a diagnostic platform technology that delivers against the market requirements of a quantitative point of care product for use across a range of clinical applications, including human and veterinary diagnostic applications. It develops, manufactures, and supplies tests and readers. The company was formerly known as Argento Diagnostics Ltd. and changed its name to AgPlus Diagnostics Ltd. in September 2012. The company was founded in 2009 and is headquartered in Sharnbrook, United Kingdom.

Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation of advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.

Antiverse is building a world-first computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates in one day. A combination of state of the art machine learning and cell-free protein synthesis is used to predict antibodies that bind to a given antigen target with high affinity. The resulting software can then take antigen taget sequence, provided by the customer, and do a high-throughput screening of all possibilities of antibody sequences to detect the sequence that will produce a high-affinity antibody for the target. The customer will be provided with the sequence in a single day, thus reducing the time typically required for antibody therapeutics discovery by 3 to 18 months.

Linear Diagnostics Limited is a diagnostics company based in Birmingham, United Kingdom, that specializes in developing a novel diagnostic platform technology leveraging linear dichroism (LD). Founded in 2011, the company focuses on a wide range of applications, including the detection of antibiotic resistance in infections and the identification of bacteria responsible for crop spoilage. The platform enables simultaneous measurement of multiple targets from a single sample and utilizes various molecular recognition methods to enhance detection capabilities. Additionally, Linear Diagnostics offers a handheld reader for measuring linear dichroism signals, providing a streamlined and efficient approach to molecular diagnostics. The technology represents a significant advancement over existing methods, facilitating quicker and more accurate testing processes.

Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.

Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.

Tropic Biosciences UK LTD is a biotechnology company focused on developing high-performing commercial varieties of tropical crops, specifically targeting the coffee and banana industries. Established in 2016 and headquartered in Norwich, United Kingdom, the company employs advanced non-GMO gene editing technologies to enhance crop performance while promoting grower wellbeing and consumer health. Through its innovative approach, Tropic Biosciences aims to improve sustainable agricultural practices and address the challenges faced by tropical crop producers.

MicrofluidX Ltd develops a cell bioprocessing platform for autologous cell and gene therapy manufacturing. The company provides a microfluidic bioprocessing system that combines multiple cell culture capabilities, such as seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting in one closed system. Its automated and closed technology allows biologists to carry out process development by running dozens of cell culture conditions. The company was incorporated in 2018 and is based in London, United Kingdom.

Ikarovec is developing novel gene therapies to treat major ophthalmic indications.

Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available.

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation of advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.

The problem of Needle Stick Injuries (NSI's) is well known throughout medical practice worldwide. However despite nearly two decades of work and legislation in the USA, Europe and other countries, the incidents of NSI's have not fallen as fast or as far as was hoped C-Major Medical was established with the sole purpose of developing a new range of safety devices that will enable, hospitals, clinics and medical practicioners everywhere to prevent NSI's.

Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

Life sciences smart data management and analysis solutions

Antiverse is building a world-first computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates in one day. A combination of state of the art machine learning and cell-free protein synthesis is used to predict antibodies that bind to a given antigen target with high affinity. The resulting software can then take antigen taget sequence, provided by the customer, and do a high-throughput screening of all possibilities of antibody sequences to detect the sequence that will produce a high-affinity antibody for the target. The customer will be provided with the sequence in a single day, thus reducing the time typically required for antibody therapeutics discovery by 3 to 18 months.

Tropic Biosciences UK LTD is a biotechnology company focused on developing high-performing commercial varieties of tropical crops, specifically targeting the coffee and banana industries. Established in 2016 and headquartered in Norwich, United Kingdom, the company employs advanced non-GMO gene editing technologies to enhance crop performance while promoting grower wellbeing and consumer health. Through its innovative approach, Tropic Biosciences aims to improve sustainable agricultural practices and address the challenges faced by tropical crop producers.

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation of advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.

Glialign specializes in regenerative technologies aimed at enhancing peripheral nerve repair. The company is developing a novel cell therapy that serves as a living nerve growth guide, designed to replace traditional nerve grafts, which often require harvesting nerves from other body parts. Current treatments for peripheral nerve injuries are only effective in less than half of the cases, highlighting the need for more reliable solutions. Glialign's approach provides an off-the-shelf alternative, enabling healthcare providers to facilitate nerve regeneration and improve functional recovery for patients suffering from nerve injuries.

Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.

Life sciences smart data management and analysis solutions

MIRICO Ltd. is a UK-based laser spectroscopy instrumentation company formed in 2015 as a spin-out from the Science and Technology Facilities Council. The technology underpinning MIRICO was developed by the RAL Space Laser Spectroscopy Team, led by Dr. Damien Weidmann. The laser spectroscopy team consists of 8 senior scientists who carry out cutting edge research and development. Over the years they have developed a range of spectroscopy techniques that overcome the major downfalls of current technologies. The company was formed to commercialise and take these technologies to market.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

Camstech Ltd is an early stage company developing novel biochemical sensing technologies. Having graduated from the CERN Business Incubation Centre at Harwell Campus in Oxfordshire, the company is now based at STFC’s Campus Technology Hub, Daresbury Laboratory. Camstech was established in 2014 with a vision to commercialise a novel sensing technology developed by Professor Pankaj Vadgama, initially for life sciences research and subsequently for applications in biotechnology and medical diagnostics.

SFH Oxford Ltd. is a company based in Didcot, United Kingdom, specializing in innovative healthcare technology aimed at improving the management of venous leg ulcers. The company develops and markets GraduCheck, a sensor-based technology that enhances the application of compression bandages, thereby increasing healing rates and patient compliance while maintaining cost-effectiveness. In addition to GraduCheck, SFH Oxford offers anatomic focus technology graduated compression socks and K-gel wound dressings. With a strong leadership team experienced in medical device technology and wound care, SFH Oxford is committed to delivering quality care for patients suffering from chronic wounds. Their products are currently undergoing clinical and field trials, demonstrating promising results in real-world applications.

MyoDOPA is develops a novel therapeutic profile providing efficient treatment.

Cagen is a synthetic biology company.

The problem of Needle Stick Injuries (NSI's) is well known throughout medical practice worldwide. However despite nearly two decades of work and legislation in the USA, Europe and other countries, the incidents of NSI's have not fallen as fast or as far as was hoped C-Major Medical was established with the sole purpose of developing a new range of safety devices that will enable, hospitals, clinics and medical practicioners everywhere to prevent NSI's.

Pireta Ltd is a company focused on developing and commercializing technology for smart textiles. Established in 2017 and based in Teddington, United Kingdom, Pireta has created a unique additive process that integrates conductivity and sensors into fabrics without altering their feel or performance. This innovative approach enables the production of textiles that can serve various functions, including communication, physiological monitoring, and tracking. Pireta's technology is applicable across multiple industries, such as military, emergency services, defense, fashion, athletics, healthcare, biosciences, and RFID tagging, facilitating the creation of wearable smart garments and electronic textiles.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

Puraffinity was incorporated in 2015 and is headquartered in London. The company specialises in the design of advanced materials, and has developed a bio-based novel adsorbent capable of removing highly challenging pollutants from contaminated water and wastewater. The technology utilises advanced supramolecular chemistry methods to functionalise bio-based materials designed to bind target chemicals. The company is at the forefront of developing solutions for overcoming imminent water quality challenges, whilst sustainable and positive environmental impact lies at the heart of the company’s ethos.

Tropic Biosciences UK LTD is a biotechnology company focused on developing high-performing commercial varieties of tropical crops, specifically targeting the coffee and banana industries. Established in 2016 and headquartered in Norwich, United Kingdom, the company employs advanced non-GMO gene editing technologies to enhance crop performance while promoting grower wellbeing and consumer health. Through its innovative approach, Tropic Biosciences aims to improve sustainable agricultural practices and address the challenges faced by tropical crop producers.

Cytox Limited is focused on developing products and services aimed at addressing neurodegenerative disorders, particularly Alzheimer's disease (AD). The company specializes in cellular and genetic assays that facilitate the diagnosis and treatment of AD, leveraging the cell division cycle theory of its pathogenesis. It has created a genetic-based blood test designed for early-stage risk assessment and diagnosis of Alzheimer's disease. Cytox also offers biomarker and drug-screening services to pharmaceutical companies engaged in clinical trials for AD and mild cognitive impairment treatments. By collaborating with Affymetrix, a part of Thermo Fisher Scientific, Cytox supports the development of novel therapeutics aimed at combating this growing condition, which currently affects millions worldwide. Founded in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox serves a global clientele that includes pharmaceutical and biotechnology firms, as well as research laboratories.

Linear Diagnostics Limited is a diagnostics company based in Birmingham, United Kingdom, that specializes in developing a novel diagnostic platform technology leveraging linear dichroism (LD). Founded in 2011, the company focuses on a wide range of applications, including the detection of antibiotic resistance in infections and the identification of bacteria responsible for crop spoilage. The platform enables simultaneous measurement of multiple targets from a single sample and utilizes various molecular recognition methods to enhance detection capabilities. Additionally, Linear Diagnostics offers a handheld reader for measuring linear dichroism signals, providing a streamlined and efficient approach to molecular diagnostics. The technology represents a significant advancement over existing methods, facilitating quicker and more accurate testing processes.

Nemesis Bioscience Ltd. is a biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic agents that restore antibiotic sensitivity in resistant microbial pathogens. Founded in 2014, the company specializes in its innovative Nemesis Symbiotics, which are designed to directly kill pathogenic microorganisms or enhance their susceptibility to existing antibiotics. This technology addresses all classes of antibiotics and various resistance mechanisms, aiming to prevent the spread of resistance genes and maintain the effectiveness of both current and future antibiotics. In addition to treating infections, Nemesis Bioscience's solutions also have potential applications in reducing chemotherapy toxicity and inactivating virulence factors. The company has received recognition for its entrepreneurial efforts, including an award from King’s College, Cambridge, and has filed multiple international patent applications to protect its inventions.

The Electrospinning Company is a leading edge provider of electrospun nanofibre innovations, developing solutions to industrial challenges. They also work closely with academic research groups to develop novel nano-scale fibres and coatings for scientific research.

AgPlus Diagnostics Ltd. develops a diagnostic platform technology that delivers against the market requirements of a quantitative point of care product for use across a range of clinical applications, including human and veterinary diagnostic applications. It develops, manufactures, and supplies tests and readers. The company was formerly known as Argento Diagnostics Ltd. and changed its name to AgPlus Diagnostics Ltd. in September 2012. The company was founded in 2009 and is headquartered in Sharnbrook, United Kingdom.

Keit Ltd. is a company based in Didcot, United Kingdom, that specializes in the design and manufacture of spectrometers and related instruments for a range of applications, spanning from ultraviolet to far infrared rays. Established in 2012, Keit has developed the microFTS®, a compact, lightweight, and rugged Fourier Transform Infrared (FTIR) spectrometer. Originally designed for space applications, the microFTS® is capable of operating in extreme environments and sets a new standard for real-time liquid-state analyses across various industries, including pharmaceuticals, chemicals, oil and gas, and food and beverage. The company also provides instruments for measuring signal levels, vibrations, and various species in gases or liquids, enhancing analytical capabilities in diverse settings.

MIRICO Ltd. is a UK-based laser spectroscopy instrumentation company formed in 2015 as a spin-out from the Science and Technology Facilities Council. The technology underpinning MIRICO was developed by the RAL Space Laser Spectroscopy Team, led by Dr. Damien Weidmann. The laser spectroscopy team consists of 8 senior scientists who carry out cutting edge research and development. Over the years they have developed a range of spectroscopy techniques that overcome the major downfalls of current technologies. The company was formed to commercialise and take these technologies to market.

Jupiter Diagnostics offers a faster, cheaper way to obtain accurate blood tests. Our patent- protected reader can replace the lab, delivering multiple tests in 10 minutes, from a prick of blood, at prices a third cheaper.

Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

Oxford Space Systems Limited is a space technology company based in Harwell, United Kingdom, founded in 2013. The firm specializes in developing, manufacturing, and marketing deployable hardware structures for space applications, including deployable antennas, composite linear boom systems, and hinge systems. By employing innovative design techniques, such as origami, and utilizing novel proprietary materials, Oxford Space Systems creates products that are lighter, less complex, and more cost-effective than traditional alternatives. The company has achieved significant milestones, including a record for the fastest development of a new product, the AstroTube Boom, which was successfully deployed in orbit within 30 months. With a team of 18 professionals possessing over 100 years of combined experience in the space sector, Oxford Space Systems has engaged in various collaborations, including government-supported projects with leading European satellite manufacturers and commercial contracts in Asia and the U.S. In 2018, the company relocated to a custom facility within the Harwell Space Cluster, enhancing its capabilities to meet security standards for defense and security contracts.

Perfectus Biomed is a microbiological services provider that specializes in customized and accredited microbiology testing. The company focuses on tailoring antimicrobial assays and developing bespoke methods for biofilm testing, recognizing that standard testing may not be suitable for all products. By adopting a research-based approach, Perfectus Biomed collaborates closely with clients to meet their specific testing needs while ensuring rapid turnaround times. Their customer-centric service includes regular feedback, consultancy, method development, and comprehensive report writing. Additionally, they produce conference abstracts and posters based on their research findings, reinforcing their commitment to delivering high-quality, personalized microbiological testing solutions.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.

NorthRow (formerly Contego) is a web-based platform that enables its users to simplify and improve the quality of risk, compliance, and anti-fraud decisions. It contains a range of features that can be used separately or in combination. It allows its users to run detailed checks on people, companies, and ID documents in order to optimize business processes, reduce risk, and help ensure compliance. The platform helps confirm identity for numerous risk factors, access multiple data sources to authenticate businesses, and verify passports, visa papers, and other documents.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

Spectral Edge combines patented Image Fusion tech with Deep Learning to reveal more of the color, detail and clarity in any image.

Tokamak Energy Ltd is a private company based in Abingdon, United Kingdom, focused on the development of fusion power technology. Established in 2009, it specializes in creating compact fusion reactors known as spherical tokamaks, which offer a more efficient means of achieving high plasma pressure compared to traditional designs. The company's key products, the ST25 and ST40, utilize high-temperature superconductors and advanced materials to enhance plasma confinement and overall reactor performance. By leveraging decades of scientific research, Tokamak Energy aims to accelerate the commercial viability of fusion energy, positioning itself as a leader in the pursuit of affordable and sustainable energy solutions that contribute to global energy security while minimizing environmental impact.

Claresys Ltd. specializes in developing and supplying lens solutions tailored for covert surveillance. The company offers a range of products, including covert pinhole pan/tilt/zoom lenses designed for C mount 1/3” sensor cameras and miniature pinhole camera lenses. Additionally, Claresys creates custom lenses suited for long-range surveillance and challenging environments, such as those involving nuclear and high-temperature conditions. Their optical technologies are utilized in diverse surveillance applications, from close monitoring in buildings and vehicles to extended stake-outs. Claresys primarily serves customers in the defense, homeland security, and police sectors, and its products are marketed through a network of distributors across several countries, including the United Kingdom, the United States, Australia, Singapore, and various European nations. Established in 2007, Claresys is headquartered in Abingdon, United Kingdom.

NorthRow (formerly Contego) is a web-based platform that enables its users to simplify and improve the quality of risk, compliance, and anti-fraud decisions. It contains a range of features that can be used separately or in combination. It allows its users to run detailed checks on people, companies, and ID documents in order to optimize business processes, reduce risk, and help ensure compliance. The platform helps confirm identity for numerous risk factors, access multiple data sources to authenticate businesses, and verify passports, visa papers, and other documents.

Life sciences smart data management and analysis solutions

Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by the real-world impact of CRISPR technology. They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.

Perfectus Biomed is a microbiological services provider that specializes in customized and accredited microbiology testing. The company focuses on tailoring antimicrobial assays and developing bespoke methods for biofilm testing, recognizing that standard testing may not be suitable for all products. By adopting a research-based approach, Perfectus Biomed collaborates closely with clients to meet their specific testing needs while ensuring rapid turnaround times. Their customer-centric service includes regular feedback, consultancy, method development, and comprehensive report writing. Additionally, they produce conference abstracts and posters based on their research findings, reinforcing their commitment to delivering high-quality, personalized microbiological testing solutions.

SFH Oxford Ltd. is a company based in Didcot, United Kingdom, specializing in innovative healthcare technology aimed at improving the management of venous leg ulcers. The company develops and markets GraduCheck, a sensor-based technology that enhances the application of compression bandages, thereby increasing healing rates and patient compliance while maintaining cost-effectiveness. In addition to GraduCheck, SFH Oxford offers anatomic focus technology graduated compression socks and K-gel wound dressings. With a strong leadership team experienced in medical device technology and wound care, SFH Oxford is committed to delivering quality care for patients suffering from chronic wounds. Their products are currently undergoing clinical and field trials, demonstrating promising results in real-world applications.

Tokamak Solutions UK Ltd. engages in providing technology for fusion neutron source to transmute nuclear waste. The company was founded in 2009 and is based in Abingdon, United Kingdom.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.

P2i is the world leader in liquid repellent nano-coating technology. The company’s revolutionary plasma process reduces the surface energy of a material so that when liquids come into contact with it, they form beads and simply roll off. P2i’s customers can improve the performance of their products by protecting them from the effects of water and other liquids without affecting their look or feel. P2i’s plasma processing machines have been sold into the textile, consumer electronics, filtration, and bioconsumables markets.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Microbial Solutions Limited offers a technology that can provide on-site treatment and disposal of MWFs which can unlock and release the replacement value of both the existing treatment technology and the associated logistics costs. The Microcycle™ technology is a powerful, patented biological degradation process that reduces waste MWFs to acceptable COD concentrations, removes toxicity and allows for the safe disposal of MWF as grey water to sewers on site. Through their offering, Microbial Solutions seeks to help their clients to cost-effectively meet their environmental responsibilities and to provide regulators with the tools to implement the regulations enshrining those responsibilities.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.

Orbital Optics specializes in the manufacture and sale of high-resolution space cameras designed for space missions, both in the United Kingdom and internationally. The company produces compact and affordable optical systems that deliver high-quality images. In addition to its camera manufacturing, Orbital Optics offers consultancy services related to imaging systems and optical payloads, ensuring clients receive expert guidance on their projects. The company also provides access to supporting ground station facilities, further enhancing its capability to support various space-related initiatives.

Oxsensis Ltd. produces non-electrical sensor systems that enable measurements to be made at the extremes of electromagnetic interference and temperature. The company offers optical pressure sensor systems for real-time measurement of dynamic pressure sensor systems, dynamic and static pressure with temperature, and static pressure sensor systems; temperature transducers; and optical accelerometers. Its products are used in aerospace, power generation, oil and gas, reciprocating engine, space, and nuclear industries. The company was founded in 2003 and is based in Didcot, United Kingdom. It has additional offices in the United States, Russia, China, and Japan.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.

Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.

Alopa is a pioneer and leader in the design, development, and deployment of infrastructure software solutions for end-to-end activation, management, and assurance of digital services over cable. Alopa Networks has been an industry driver in developing operations support software (OSS) solutions for broadband service providers that accelerate time-to-market for advanced network-based services and applications, including Internet telephone (VoIP), differentiated access, security, multimedia, and more. Alopa's combined family of products automates the complete life cycle of subscriber acquisition and service management by facilitating service creation, deployment, and assurance and security functions while, at the same time, accelerating revenue and lowering operating and capital expenses. Its flagship Alopa MetaServ(TM) platform is currently the only industry solution that automates the entire subscriber life cycle -- from equipment qualification through service creation and activation to customer support -- and integrates all layers of the IT infrastructure, including billing, order entry, customer care, and network management. It also provides secure provisioning for both PacketCable(TM) and CableHome(TM) networks, offering a framework for VoIP, multimedia services, and interactive gaming.